Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) EBITDA Margin (2021 - 2025)

Janux Therapeutics (JANX) has disclosed EBITDA Margin for 5 consecutive years, with 234.98% as the latest value for Q3 2025.

  • Quarterly EBITDA Margin rose 400466.0% to 234.98% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 1114.72% through Dec 2025, down 47724.0% year-over-year, with the annual reading at 1114.72% for FY2025, 47724.0% down from the prior year.
  • EBITDA Margin for Q3 2025 was 234.98% at Janux Therapeutics, up from 4239.64% in the prior quarter.
  • The five-year high for EBITDA Margin was 79.25% in Q2 2024, with the low at 4239.64% in Q3 2024.
  • Average EBITDA Margin over 5 years is 1000.5%, with a median of 831.01% recorded in 2023.
  • The sharpest move saw EBITDA Margin plummeted -377547bps in 2024, then skyrocketed 400466bps in 2025.
  • Over 5 years, EBITDA Margin stood at 848.39% in 2021, then surged by 37bps to 538.59% in 2022, then increased by 25bps to 403.01% in 2023, then crashed by -952bps to 4239.64% in 2024, then surged by 94bps to 234.98% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 234.98%, 4239.64%, and 79.25% for Q3 2025, Q3 2024, and Q2 2024 respectively.